Got it, thanks.
It's not clear from the article if they were able to differentiate between the different vaccines. The study looks like it did not include the J&J one. I guess I was trying to provide clarity as to why the J&J specifically would be suspended. This study seems to only indicate that vaccines taken as a whole are safer than covid when it comes to this specific clotting risk. Not necessarily the J&J or AstraZeneca. Unless I'm missing something.
"Though the analyses for the three vaccines are based on different data sets, making comparisons difficult, the study suggests that the risk of a clot among those with the disease is about eight to 10 times higher than after vaccination."
Also, the comparison made here seems to be the entire population averaged together. Not differentiated by age/sex. The issue with the J&J seems to be in 18-50 year old females. Is the same clotting risk higher from covid than the vaccine for that specific group? Maybe, but this article doesn't say that, unless I'm missing something.
"The relative benefits of the AstraZeneca shot, compared with the risk of clots, decrease when doses are given to younger adults, according to an analysis by the U.K.’s Medicines and Healthcare Products Regulatory Agency."
This line seems significant as well. It didn't yet cover issues that showed up after the 2nd dose. It's also possible cases could pop up further out than 2 weeks from covid diagnosis.
"The authors of the Oxford study counted the number of cerebral venous thrombosis cases diagnosed in the two weeks after Covid diagnosis and after the first dose of a vaccine. "
“All the evidence we have is that risks of Covid are so much greater than whatever the risks of the vaccines might be,” Paul Harrison
That might be true, but this study didn't show that for the AstraZeneca & J&J vaccines. It looks like it is true for the Pfizer and Moderna versions. It also shouldn't be a "one-size fits all" statement when the article itself says that "
The relative benefits of the AstraZeneca shot, compared with the risk of clots, decrease when doses are given to younger adults".